The body's own cannabinoids killed glioblastoma cells by disrupting their mitochondria, through a receptor pathway beyond the usual cannabinoid targets

Anandamide (AEA) and oleamide (ODA) reduced glioblastoma cell viability and increased lipid peroxidation compared to normal astrocytes. Both reduced mitochondrial membrane potential and impaired Complex I activity in C6 cells. The PPAR-gamma antagonist GW9662 showed differential effects, indicating PPAR-gamma involvement varies by cell type.

In vitro study using two glioblastoma cell lines (C6 and RG2) and primary astrocyte cultures as non-tumor controls. Cell viability, lipid peroxidation, mitochondrial membrane potential, and Complex I activity were measured after AEA and ODA treatment, with and without the PPAR-gamma antagonist GW9662.

Unlike the CBD kidney cancer study (RTHC-08638), these endocannabinoids showed selectivity for cancer cells over normal brain cells, and they work through a non-classical receptor pathway (PPAR-gamma) that could be more therapeutically accessible.

Glioblastoma remains one of the most lethal cancers. The finding that endocannabinoids selectively target cancer cell mitochondria through PPAR-gamma, rather than classical CB1/CB2 receptors, opens a distinct therapeutic avenue from traditional cannabinoid approaches.

In vitro study only. Two glioblastoma cell lines showed different responses, suggesting results are cell-type dependent. Endocannabinoid concentrations used may not reflect physiological brain levels. Primary astrocytes may not perfectly represent all normal brain cell types.